3D Wind AG: Generate green energy yourself - with the bionic wind turbine VAYU®

(Muri-Bern, Switzerland): If you own a home or a business and want to supply yourself with green energy, you should rely on Swiss technology: The company 3D Wind AG has developed VAYU®, a wind turbine that puts conventional turbines in the shade.
In times of climate change and high energy prices, there is much to be said for taking power generation for one's own needs into one's own hands - with a CO2-neutral wind turbine. Reservations about such wind turbines on one's own roof include too much noise, hardly any efficiency or the danger to birds. The Bern-based company 3D Wind AG has found innovative answers to these problems with its VAYU® turbine: VAYU® is compact, silent and generates green energy around the clock when the wind blows - according to information, it is the world's first wind turbine with a new patented 3-dimensional motion technology that delivers electricity almost silently with a pleasantly harmonious and bionic motion.
In this way, it remains true to its environmentally conscious style: "Visually, the turbine is reminiscent of dragonfly wings," says Theo H. Grepper, founder of 3D Wind AG. Yet the VAYU®, which is available in several colors, combines physical superiority with mechanical simplicity: the individual blades also rotate on their axis. This leads to higher efficiency than with conventional 2D drives.
Whether on your own home, on industrial buildings or on fields, hills, or gardens: YAVU® can be placed anywhere. The turbine's technology can be combined with solar panels to generate electricity even in low wind conditions. And there is something else that sets VAYU® apart from horizontal and vertical 2D wind turbines: The innovation from Switzerland offers up to 40 percent higher efficiency in power generation - even in low wind conditions.
"We are convinced that our wind turbine is the solution to previous sustainability problems," explains Theo Grepper. The way the turbine moves is revolutionary and symbolizes the connection between man and nature.
3D Wind AG was founded in 2017 by Theo Grepper. The spin-off company is dedicated to developing solutions for the production of green energy from wind technologies. You can find more information on our website and connect with us on LinkedIn
Contacts
3D Wind AG
Frau Sophie Quenet
Worbstrasse 97
3074 Muri-Bern
+41 31 954 28 00
Images

About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
